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Client-owned pet dogs represent exceptional translational
models for advancement of Cancer Research, as they
reflects the complex heterogeneity observed in human
cancer. We have recently shown that a genetic vaccine
targeting dog telomerase (dTERT) and based on Ad/
DNA-EGT technology can induce strong cell-mediated
immune responses against this tumor antigen and increase
overall survival of dogs affected by B-cell lympho-
sarcoma (LSA) in comparison with historical controls
when combined with COP chemotherapy regimen. Here,
we have conducted a double arm clinical trial with an
extended number of LSA patients, measured the antigen-
specific immune response and evaluated potential toxic
effects of the immunotherapy along with a follow up of
patients survival for three years and half. The immune
response was measured by ELISPOT. The expression of
dTERT was quantified by quantitative PCR. Changes in
hematological parameters, local/systemic toxicity or
organic dysfunction and fever were monitored over time
during the treatment. dTERT-specific cell mediated
immune responses were induced in almost all treated
animals. No adverse effects were observed in any dog
patient that underwent treatment. The overall survival
time of vaccine/COP treated dogs was significantly
increased over the COP-only treated cohort (>76.1 vs
29.3 weeks, respectively, p<0.0001). There was a significant
association between dTERT expression levels in LSA cells
and overall survival (OS) among vaccinated patients. In
conclusion, Ad/DNA-EGT-based cancer vaccine against
dTERT in combination with COP chemotherapy is safe
and significantly prolongs the survival of LSA canine
patients. These data confirm the therapeutic efficacy of
dTERT vaccine and support the evaluation of this
approach for other cancer types as well as the translation
of this approach to human clinical trials.
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